Eton Pharmaceuticals, Inc. (Nasdaq:ETON) announced on Friday that it has acquired Galzin (zinc acetate), an FDA-approved maintenance treatment for patients with Wilson Disease initially treated with a chelating agent.
Wilson Disease affects fewer than 5,000 patients in the United States. Eton plans to begin US commercialization in Q1 2025, leveraging its metabolic sales force to support healthcare providers treating this rare condition.
Eton will offer Galzin through its Eton Cares patient support program, featuring a USD0 co-pay for qualified commercial patients, insurance benefits investigation, educational resources and prescription fulfilment. European rights to the product, commercialized as Wilzin by a third party, are also part of the acquisition. Under an existing agreement, Eton will continue supplying the product while the third party handles European commercialization.
Stifel acted as the exclusive financial advisor to Eton for this transaction.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval